Non-invasive methods to assess biomarkers of exposure and early stage of pulmona disease in smoking subjects

Monaldi Archives for Chest Disease - Pulmonary Series

Volumn 69, Issue 3, 2008, Pages 128-133

  Malerba, Mario ^a   Ragnoli, B ^a   Corradi, M ^b  

^a UNIVERSITY OF BRESCIA   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

Author keywords

Chronic obstructive pulmonary disease (COPD); Cigarette smoke; Early lung damage; Exhaled breath condensate (EBC); Exhaled nitric oxide (eNO); Induced sputurn (IS)

Indexed keywords

BIOLOGICAL MARKER; NITRIC OXIDE;

BREATH ANALYSIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; DISEASE ACTIVITY; DISEASE SEVERITY; ENVIRONMENTAL EXPOSURE; EXHALATION; HUMAN; NON INVASIVE PROCEDURE; OXIDATIVE STRESS; REVIEW; SPUTUM; TOBACCO;

EID: 57849106753     PISSN: 11220643     EISSN: 2465101X     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. Sherrill DL, Lebowitz MD, Burrows B. Epidemiology of chronic obstructive pulmonary disease. Clin Chest Med 1990; 11: 375-388.
2. Kharitonov SA. Exhaled markers of inflammatory lung diseases: ready for routine monitoring? Swiss Med Wkly 2004; 134: 175-92.
3. Liu J, Thomas PS. Exhaled breath condensate as a method of sampling airway nitric oxide and other markers of inflammation. Med Sci Monit 2005; 11: MT53-62. 2005.
4. Kharitonov AS, Barnes PJ. Exhaled biomarkers. Chest 2006; 130: 1541-1546.
5. Balbi B, Pignatti P, Corradi M, et al. Bronchoalveolar lavage, sputum and exhaled clinically relevant inflammatory markers: values in healthy adults. Eur Respir J 2007; 30: 769-781.
6. ATS/ERS Recommendations for Standardized Procedures for the Online and Offline Measurement of Exhaled Lower Respiratory Nitric Oxide and Nasal Nitric Oxide. Am J Respir Crit Care Med 2005; 171: 912-930.
7. Van Amsterdam JGC, Nierkens S, Vos SG, et al. Exhaled nitric oxide: a novel marker of adverse respiratory health effect in epidemiological studies. Arch Environ Health 2000; 55: 418-23.
8. Henriksen AH, Sue-Chu M, Lingaas TH, et al. Exhaled and nasal NO levels in allergic rhinitis: relation to sensitisation, pollen season and bronchial hyperresponsiveness. Eur Respir J 1999; 13: 301-306.
9. Martin U, Bryden K, Devoy M, et al. Increased levels of exhaled NO during nasal and oral breathing in subjects with seasonal rhinitis. J Allergy Clin Immunol 1996; 97: 768-772.
10. Hoyt JC, Robbins RA, Habib M, et al. Cigarette smoke decreases inducible nitric oxide synthase in lung epithelial cells. Exp Lung Res 2003; 29: 17-28.
11. Demoncheaux EA, Maniscalco M, Roe S, et al. Exhaled NO: ideas on its origin and physiological meaning. In: Weir E, Archer SL, Reeves JT (Eds). Nitric Oxide and Oxygen Radicals in the Pulmonary Vasculature. New York: Futura,1996: pp 427-45.
12. Lundberg JO, Weitzberg B, Lundberg JM, Alving K. Nitric oxide in exhaled air. Eur Respir J 1996; 9: 2671-80.
13. Olivieri M, Talamini G, Corradi M, et al. Reference values for exhaled nitric oxide (reveno) study. Respir Res 2006, 7: 94.
14. Horvath I, Donnelly LE, Kiss A, Balint B, Kharitonov SA, Barnes PJ. Exhaled nitric oxide and hydrogen peroxide concentrations in asthmatic smokers. Respiration 2004; 71: 463-8.
15. Kharitonov SA, Robbins RA, Yates D, Keatings V, Barnes PJ. Acute and chronic effects of cigarette smoking on exhaled nitric oxide. Am Respir Crit Care Med 1995; 152: 609-12.
16. Maniscalco M, Di Mauro V, Farinaro E, Carratu L, Sofia M. Transient decrease of exhaled nitric oxide after acute exposure to passive smoke in healthy subjects. Arch Environ Health 2002; 57: 437-40.
17. Yates DH, Breen H, Thomas PS. Passive smoke inhalation decreases exhaled nitric oxide in normal subjects. Am J Respir Crit Care Med 2001; 164: 1043-6.
18. Högman M, Holmkvist T, Walinder R, et al. Increased nitric oxide elimination from the airways after smoking cessation. Clin Sci (Lond) 2002; 103: 15-9.
19. Robbins RA, Millatmal T, Lassi K, Rennard S, Daughton D. Smoking cessation is associated with an increase in exhaled nitric oxide. Chest 1997; 112: 313-8.
20. Van der Vaart H, Postma DS, Timens W, et al. Acute effects of cigarette smoking on inflammation in healthy intermittent smokers. Respir Res 2005; 6-22.
21. McCrea KA, Ensor JE, Nall K, et al. Altered cytokine regulation in the lungs of cigarette smokers. Am J Respir Crit Care Med 1994; 150: 696-703.
22. Barnes PJ. Nitric oxide and airway disease. Ann Med 1995, 27: 389-393.
23. Langen RC, Korn SH, Wouters EF. ROS in the local and systemic pathogenesis of COPD. Free Radic Biol Med 2003, 35: 226-235.
24. Rahman I, MacNee. Role of oxidants/antioxidants in smoking-induced lung diseases. Free Radical Biol Med 1996, 21: 669-681.
25. Maestrelli P, Saetta M, Mapp CE, Fabbri LM. Remodelling in response to infection and injury. Airway inflammation and hypersecretion of mucus in smoking subjects with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: Suppl. 10, 76-80.
26. Keatings VM, Collins PD, Scott PD, Barnes PJ. Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med 1996; 156: 530-534.
27. Hill AT, Bayley DL, Campbell EJ, Hill SL, Stockley RA. Airways inflammation in chronic bronchitis: the effects of smoking and alpha1-antitrypsin deficiency. Eur Respir J 2000; 15: 886-890.
28. Zijlstra FJ, Vincent JE, Mol WM, Hoogsteden HC, Van Hal PT, Jongejan RC. Eicosanoid levels in bronchoalveolar lavage fluid of young female smokers and non-smokers. Eur J Clin Invest 1992; 22: 301-306.
29. Takanashi S, Hasegawa Y, Kanehira Y, et al. IL-10 level in sputum is reduced in bronchial asthma, COPD and in smokers. Eur Respir J 1999; 14: 309-314.
30. Domegala-Kulawik J, Maskey-Warzechowska M, Kraszewska I, et al. The cellular composition and macrophage phenotype in induced sputum in smokers and ex-smokers with COPD. Chest 2003; 123: 1054-1059.
31. Rytila P, Rehn T, Ilumets H, et al. Increased oxidative stress in asymptomatic current chronic smokers and GOLD Stage 0 COPD. Respir Res 2006; 7: 69.
32. Aviles B, Belda J, Margarit G, et al. Markers of airway remodeling in induced sputum from healthy smokers. Arch Broncopneumol 2006; 42: 235-40.
33. Babusyte A, Stravinskaite K, Jeroch J, et al. Patterns of airway inflammation and MMP-12 expression in smokers and ex-smokers with COPD. Respir Res 2007; 8: 81.
34. Rovina N, Papapetropoulos A, Kollintza A, et al. Vascular endothelial growth factor: an angiogenic factor reflecting airway inflammation in healthy smokers and in patients with bronchitis type of chronic obstructive pulmonary disease? Respir Res 2007, 8: 53.
35. Mutlu GM, Garey KW, Robbins RA, et al. Collection and analysis of exhaled breath condensate in humans. Am J Respir Crit Care Med 2001; 164: 731-737.
36. Montuschi P, Barnes PJ. Analysis of exhaled breath condensate for monitoring airway inflammation. Trends Pharmacol Sci 2002; 23: 232-7.
37. Mutti A, Corradi M. Recent developments in human biomonitoring: non-invasive assessment of target tissue dose and effects of pneumotoxic metals. Med Lav 2006; 97: 199-206.
38. NRC (National Research Council). Biological markers in environmental health research. Environ Health Perspect 1987; 74: 1-19.
39. Montuschi P. Exhaled breath condensate analysis in patients with COPD. Clinica Chimica Acta 2005; 356: 22-34.
40. Lewis GP, Lyle H, Miller S. Association between elevated hepatic water-soluble protein-bound cadmium levels and chronic bronchitis and-or emphysema. Lancet 1969; 2: 1330-3.
41. Hirst RN Jr, Perry HM Jr, Cruz MG, et al. levated cadmium concentration in emphysematous lungs. Am Rev Respir Dis 1973; 108: 30-9.
42. Grasseschi RM, Ramaswamy RB, Levine DJ, Klaassen CD, Wesselius LJ. Cadmium accumulation and detoxification by alveolar macrophages of cigarette smokers. Chest 2003; 124: 1924-8.
43. Pryor, W. A., and K. Stone. 1993. Oxidants in cigarette smoke: radicals, hydrogen peroxides, peroxynitrate, and peroxynitrite. Ann NY Acad Sci 686: 12-28.
44. Dekhuijzen RPN, Aben KKH, Dekker I, et al. Increased exhalation of hydrogen peroxide in patients with stable and unstable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996; 154: 813-816.
45. Nowak, D. Kasielski, M. Antczak, A. Pietras, T. Bialasiewicz, P. Increased content of thiobarbituric acid reactive substances and hydrogen peroxide in the expired breath condensate of patients with stable chronic obstructive pulmonary disease. No significant effect of cigarette smoking. Respir Med 93: 389-396; 1999.
46. Culpitt SV, Russell REK. The measurement of hydrogen peroxide in airway disease. Eur Respir Rev 1999; 68: 246-248.
47. Nowak D, Kalucka S, Bialasiewicz P, Krol M. Exhalation of H2O2 and thiobarbituric acid reactive substances (TBARs) by healthy subjects. Free Radic Biol Med 2001; 30: 178-86.
48. Kostikas K, Papatheodorou G, Psathakis K, Panagou P, Loukides S. pH in expired breath condensate of patients with inflammatory airway diseases. Am J Respir Crit Care Med 2002; 165: 1364-70.
49. Hoidal JR, Niewoehner DE. Lung phagocyte recruitment and metabolic alterations induced by cigarette smoke in humans and in hamsters. Am Rev Respir Dis 1982; 126: 548-552.
50. Hunninghake GW, Crystal RG. Cigarette smoking and lung destruction: accumulation of neutrophils in the lungs of cigarette smokers. Am Rev Respir Dis 1983; 128: 833-836.
51. Balbi B. COPD: is chemotaxis the key? Chest 2003; 123: 983-986.
52. Becher G, Winsel K, Beck E, Neubauer G, Stresemann E. Leukotriene B4 in breathing condensate of patients with bronchopulmonary diseases and of normal patients. Appl Cardiopulmon Pathophysiol 1995; 5: 215-219.
53. Montuschi P, Ciabattoni G, Paredi P, et al. 8-Isoprostane as a biomarker of oxidative stress in interstitial lung diseases. Am J Respir Crit Care Med 1998; 158: 1524-1527.
54. Montuschi P, Kharitonov SA, Ciabattoni G, Barnes PJ. Exhaled leukotrienes and prostaglandins in COPD. Thorax 2003; 58: 585-8.
55. Biernacki WA, Kharitonov SA, Barnes PJ. Increased leukotriene B4 and 8-isoprostane in exhaled breath condensate of patients with exacerbation of COPD. Thorax 2003; 58: 294-298.
56. Carpagnano GE, Barnes PJ, Geddes DM, Hodson ME, Kharitonov SA. Increased inflammatory markers in the exhaled breath condensate of cigarette smokers. Eur Respir J 2003; 21: 589-93.
57. Gaber F, Acevedo F, Delin I, et al. Saliva is one likely source of leukotriene B4 in exhaled breath condensate. Eur Respir J 2006; 28: 1229-35.
58. Lykkesfeldt J. Malondialdehyde as biomarker of oxidative damage to lipids caused by smoking. Clin Chim Acta 2007; 380: 50-8.
59. Munnia A, Bonassi S, Verna A, et al. Bronchial malondialdehyde DNA adducts, tobacco smoking, and lung cancer. Free Radic Biol Med 2006; 41: 1499-505.
60. Corradi M, Rubinstein I, Andreoli R, et al. Aldehydes in exhaled breath condensate of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003; 167: 1380-1386.
61. Corradi M, Pignatti P, Manini P, et al. Comparison between exhaled and sputum oxidative stress biomarkers in chronic airway inflammation. Eur Respir J 2004; 24: 1011-7.